NUMINUS WELLNESS INC - NUMIF STOCK NEWS

Numinus Wellness Inc. has announced the re-launch of its podcast, Psychedelic Therapy Frontiers, aimed at promoting education in psychedelic-assisted therapy. Hosted by experts including Dr. Stephen Thayer, Dr. Reid Robison, and Dr. Joe Flanders, the series will discuss the efficacy of psychedelic treatments for mental health issues like depression and PTSD. New episodes will air every Tuesday across major podcast platforms. This initiative enhances Numinus' commitment to integrating innovative mental health solutions into mainstream practice.

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced its participation in the Wonderland conference in Miami from November 3-5, 2022. Dr. Reid Robison, Chief Clinical Officer, will present on the neurobiological differences between classic psychedelics and ketamine on November 5 at 9:50 a.m. ET. Numinus focuses on innovative mental health treatments, facilitating access to safe psychedelic-assisted therapies and aims to integrate these therapies into mainstream clinical practice, addressing conditions like depression and anxiety.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced the launch of its Ketamine for Chronic and Serious Medical Illness Program, aimed at providing ketamine-assisted therapy to patients suffering from terminal conditions and chronic pain. Initially available in clinics across Utah, British Columbia, and Quebec, the program seeks to integrate therapy with existing care to improve overall patient wellbeing. The company is also consolidating its operations following the acquisition of Novamind, aiming for better service delivery and reduced costs.

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced that its Founder and CEO, Payton Nyquvest, will participate in a Water Tower Research Fireside Chat on October 13, 2022, at 2:30 p.m. ET. The discussion will center around Numinus' strategic acquisition of Novamind and the growth opportunities it presents. Investors can register here.

On October 5, 2022, Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced the development of a psilocybin-containing tea bag for clinical research and potential therapeutic use. Designed for accessibility, especially for patients needing palliative care, this product allows precise dosing of 25mg per use, made from validated Psilocybe cubensis strains. Numinus aims to include this product in Health Canada's psilocybin supplier list to enhance access to psychedelic-assisted therapies.

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF), a leader in mental health care, will participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022, in San Francisco. Founder and CEO Payton Nyquvest will feature in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on October 7 at 9:00 a.m. PT. Numinus will also partake in a virtual fireside chat during the Cantor Symposium on Mental Health Clinics on October 11, 2022, at 11:00 a.m. ET. The company focuses on innovative, evidence-based psychedelic-assisted therapies aimed at mental health improvement.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has launched ketamine-assisted therapy at its Neurology Centre of Toronto to assist patients with neurologic conditions. This initiative leverages NCT's established infrastructure and aims to address mental health challenges associated with neurologic disorders. The clinic will follow a modified protocol for ketamine therapy, focusing on conditions like epilepsy and concussion. Additionally, NCT is set to expand psychedelic-assisted therapy access through Health Canada's Special Access Program, which includes promising treatments like psilocybin for depression.

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) has reported significant growth following its acquisition of Novamind, which was completed on June 10, 2022. In August, the company recorded over 6,200 client appointments, a 25% increase compared to July, with 4,900 appointments at its eight US wellness clinics. Numinus is launching new financing options in Canada to enhance accessibility for clients. The company plans to rebrand its physical clinics by the end of 2022. Financial results for its fourth quarter will be disclosed on November 29, 2022.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte New York Palace Hotel. Numinus will present on September 13 at 9:00 a.m. ET. Interested attendees can register here. Numinus is dedicated to advancing mental health care through innovative and evidence-based psychedelic-assisted therapies.